Author

Amanda N. Arnold

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

Observed institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

ORCID: 0009-0007-1555-1314

Observed ORCID: 0009-0007-1555-1314

OpenAlex ID: A5086826216

Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

2025 · Saranya Chumsri, Joseph J. Larson, et al. · Clinical Cancer Research · 6

Abstract P4-01-17: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

2023 · Saranya Chumsri, Joseph J. Larson, et al. · Cancer Research · 1

Data from Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

2025 · Saranya Chumsri, Joseph J. Larson, et al.

Supplementary Table 1 from Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

2025 · Saranya Chumsri, Joseph J. Larson, et al.

Abstract 5454: Peripheral blood biomarkers in Phase II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

2023 · Saranya Chumsri, Joseph J. Larson, et al. · Cancer Research

Works count: 5

Citation count: 7

H-index: 1

I10-index: